Ketoacidosis is a metabolic emergency normally associated with type 1 diabetes, and it is not something expected in a person without diabetes at all. That makes it an unusual thing to find in the adverse event database for a weight drug. A case of exactly this kind is described on this site’s sister publication; this analysis asks how often it is being reported [1]. The wider safety profile these drugs carry in people without diabetes is surveyed in the network meta-analysis of nineteen drugs.
Both drugs produced a signal among non-diabetic users. Semaglutide had a reporting odds ratio of 3.15 (95% CI 2.78–3.56) across 261 cases, and tirzepatide 1.22 (95% CI 1.06–1.39) across 209. Roughly three quarters of the cases in each group required hospitalization.
What lifts this above the usual pharmacovigilance caveats is the population and the severity. Ketoacidosis in someone without diabetes cannot be explained away by the underlying condition the way most adverse events in a diabetes cohort can. And the hospitalization rate, above 70% in both groups, is a severity marker that disproportionality analysis does not usually supply — these are not minor coded events.
The rising trend is the part most likely to be misread. Tirzepatide reports went from one or two a quarter in 2022 to 28 to 34 a quarter by 2025, which sounds like a worsening problem. It spans precisely the period in which tirzepatide went from newly launched to one of the most prescribed drugs in the country. More users generate more reports, and nothing in this design separates a rising rate from a rising denominator — the same trap set out in the reflux reporting study.
The practical content is a symptom list rather than a probability. Persistent vomiting, abdominal pain, rapid breathing and confusion during a period of very low food intake are reasons to seek urgent care rather than to wait, particularly during dose escalation when intake falls fastest. That is the same window in which the nutritional problems in the thiamine cases arose, and it is described from the tolerability side in titration and nausea.